IPD’s Taiwanese subscription brings local expertise to this unique market, offering:

​

• Easy-to-use Taiwanese brand, biosimilar,

       and generic drug launch 

       tracking schedules
 

• Taiwanese litigation, invalidation, and
  patent-term extension dispute tracking
  alongside courtroom coverage and 
  real-time email updates

​

• ƒPersonalized consults with local Taiwanese intellectual property analysts 
   

• ƒWeekly updates including trending Taiwanese drug topics, recent publications,
  and loss-of-exclusivity information
   

• Complete drug information with locally reviewed Taiwanese indications
   

• Comprehensive Taiwanese clinical development tracking in every major disease class
   

• Taiwanese API (DMF) information